Extended cycle multiphasic oral contraceptive method

Details Extended cycle multiphasic oral contraceptive method Extended cycle multiphasic oral contraceptive method

2007-02-09

2011-11-22

Hui, San-Ming (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

C514S182000

Reexamination Certificate

active

08063030

ABSTRACT:
A multiphasic method of contraception comprising the steps of sequentially administering to a female of child bearing age a Phase I composition containing a progestogen in an amount equivalent to about 0.3 to about 1.5 mg norethindrone acetate and an estrogen in an amount equivalent to about 5 to about 15 mcg of ethinyl estradiol for about 7 to about 14 days; a Phase II composition containing a progestogen in an amount equivalent to about 0.3 to about 1.5 mg of norethindrone acetate and an estrogen in an amount equivalent to about 10 to about 25 mcg of ethinyl estradiol for about 14 to about 22 days; a Phase III composition containing a progestogen in an amount equivalent to about 0.3 to about 1.5 mg of norethindrone acetate and an estrogen in an amount equivalent to about 15 to about 35 mcg of ethinyl estradiol for about 20 to about 31 days; and an optional Phase IV composition containing (i) an estrogen in an amount equivalent to about 5 to about 20 mcg of ethinyl estradiol, or (ii) a placebo or a non-steroidal component, or (iii) a combination of (i) and (ii), for about 2 to about 8 days. The ethinyl estradiol equivalent amount of estrogen in each of the successive Phases II and III is at least 5 mcg greater than the ethinyl estradiol equivalent amount of estrogen in the immediately-preceding phase.

REFERENCES:
patent: 4962098 (1990-10-01), Boissonneault
patent: 5010070 (1991-04-01), Boissonneault
patent: RE35724 (1998-02-01), Pasquale
patent: 5756490 (1998-05-01), Lachnit et al.
patent: 5898032 (1999-04-01), Hodgen
patent: 6027749 (2000-02-01), Schmidt-Gollwitzer et al.
patent: 6251956 (2001-06-01), Kafrissen et al.
patent: 6312722 (2001-11-01), Schmidt-Gollwitzer et al.
patent: 6500814 (2002-12-01), Hesch
patent: 6797282 (2004-09-01), Kafrissen et al.
patent: 2001/0020015 (2001-09-01), Kafrissen et al.
patent: 2003/0139381 (2003-07-01), Bell et al.
patent: 2003/0219471 (2003-11-01), Caubel et al.
patent: 2003/0225048 (2003-12-01), Caubel et al.
patent: 2004/0142914 (2004-07-01), Friedman et al.
patent: 2004/0202713 (2004-10-01), Van Beek et al.
patent: 2004/0220152 (2004-11-01), Ben-Maimon et al.
patent: 2005/0064031 (2005-03-01), Stockemann et al.
patent: 2005/0090475 (2005-04-01), LaGuardia
patent: 2005/0113350 (2005-05-01), Duesterberg et al.
patent: 2005/0143359 (2005-06-01), Bell et al.
patent: 2007/0259840 (2007-11-01), Endrikat et al.
patent: 4313926 (1994-11-01), None
patent: 0770388 (1997-05-01), None
patent: 98/04268 (1998-02-01), None
patent: 2005/049142 (2005-06-01), None
patent: 2005/092441 (2005-10-01), None
patent: 2005/102247 (2005-11-01), None
patent: 2007/002910 (2007-01-01), None
Wiegratz and Kuhl, Drugs, 2004;64(21):2447-2462.
Edwards, L.A., “An Update on Oral Contraceptive Options”, Formulary, Advanstar Communications, Cleveland, OH, vol. 39, No. 2, Feb. 2004, pp. 104-121.
Foidart, Jean-Michel, et al. “The use of an oral contraceptive containing ethinylestradiol and drospirenone in an extended regimen over 126 days,” Contraception 73 (2006) 34-40.

Affiliated with

Also associated with

Rating

Extended cycle multiphasic oral contraceptive method does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Extended cycle multiphasic oral contraceptive method, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Extended cycle multiphasic oral contraceptive method will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4275798